|Articles|October 23, 2018

The Future of JAK Inhibitors Figure 1

Author(s)Denise Baldock, Elizabeth Baynton, Amanda Baskett, and Nicola Bailey

External Link - Future-of-JAKs_Figure 1.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China

ByNicholas Jacobus

August 5th 2026

For complex biologics, such as multispecific antibodies or antibody drug conjugates, the modality itself is a coordination puzzle. Credit: Stock.Adobe.com/anamejia18.

Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change

ByChristian Olsen

August 3rd 2026

Why Real-Time Data Analytics Are Vital for the Next Evolution of Clinical Trials

ByChristian Schmidt

July 31st 2026

FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study

ByNicholas Jacobus

July 31st 2026

M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK

ByNicholas Jacobus

July 30th 2026

The Future of JAK Inhibitors Figure 1

Related Content

CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China

Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change

Why Real-Time Data Analytics Are Vital for the Next Evolution of Clinical Trials

FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study

M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK

Trending on PharmExec

Amazon Pharmacy Launches GLP-1 Delivery Service

Pharmaceutical Executive Daily: Amazon Pharmacy to Offer GLP-1 Delivery Service

FDA Approves Moderna's mRNA-Based Flu Vaccine

Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition

Your Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026